Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 12 March, 2025
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo

Torrent Pharmaceuticals Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 8, 2025, 10:08 am

Market Cap 1,04,027 Cr.
Current Price 3,074
High / Low 3,591/2,488
Stock P/E55.9
Book Value 222
Dividend Yield0.91 %
ROCE23.2 %
ROE24.2 %
Face Value 5.00
PEG Ratio6.76

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Torrent Pharmaceuticals Ltd

Competitors of Torrent Pharmaceuticals Ltd

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
MPS Pharmaa Ltd 6.71 Cr. 3.51 4.33/3.05 0.800.00 %9.15 %34.9 % 10.0
Gujarat Themis Biosyn Ltd 2,663 Cr. 244 390/19250.6 20.50.27 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 53.1 Cr. 71.5 94.9/32.118.0 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 38.0 Cr. 26.0 29.0/8.7438.8 6.640.00 %2.65 %2.08 % 10.0
Godavari Drugs Ltd 70.4 Cr. 93.5 155/79.011.4 55.40.00 %14.4 %15.5 % 10.0
Industry Average17,255.37 Cr1,081.8442.42185.800.37%16.00%16.32%6.27

All Competitor Stocks of Torrent Pharmaceuticals Ltd

Quarterly Result

MetricDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Sales 2,1082,1312,3472,2912,4912,4912,5912,6602,7322,7452,8592,8892,809
Expenses 1,5701,5701,6351,6121,7671,7641,8001,8351,8631,8621,9551,9501,895
Operating Profit 538561712679724727791825869883904939914
OPM % 26%26%30%30%29%29%31%31%32%32%32%32%33%
Other Income 48-4293016-1093426553124-1633
Interest 62575569102107103918080756457
Depreciation 167162155163193196191201213203197198199
Profit before tax 357-87532463419433531559631631656661691
Tax % 30%36%33%33%30%34%29%31%30%29%30%31%27%
Net Profit 249-118354312292287378386443449457453503
EPS in Rs 7.36-3.4910.469.228.638.4811.1711.4113.0913.2713.5013.3914.86

Last Updated: February 28, 2025, 4:33 pm

Below is a detailed analysis of the quarterly data for Torrent Pharmaceuticals Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

  • For Sales, as of Dec 2024, the value is ₹2,809.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,889.00 Cr. (Sep 2024) to ₹2,809.00 Cr., marking a decrease of 80.00 Cr..
  • For Expenses, as of Dec 2024, the value is ₹1,895.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1,950.00 Cr. (Sep 2024) to ₹1,895.00 Cr., marking a decrease of 55.00 Cr..
  • For Operating Profit, as of Dec 2024, the value is ₹914.00 Cr.. The value appears to be declining and may need further review. It has decreased from 939.00 Cr. (Sep 2024) to ₹914.00 Cr., marking a decrease of 25.00 Cr..
  • For OPM %, as of Dec 2024, the value is 33.00%. The value appears strong and on an upward trend. It has increased from 32.00% (Sep 2024) to 33.00%, marking an increase of 1.00%.
  • For Other Income, as of Dec 2024, the value is ₹33.00 Cr.. The value appears strong and on an upward trend. It has increased from -16.00 Cr. (Sep 2024) to ₹33.00 Cr., marking an increase of ₹49.00 Cr..
  • For Interest, as of Dec 2024, the value is ₹57.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 64.00 Cr. (Sep 2024) to ₹57.00 Cr., marking a decrease of 7.00 Cr..
  • For Depreciation, as of Dec 2024, the value is ₹199.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 198.00 Cr. (Sep 2024) to ₹199.00 Cr., marking an increase of ₹1.00 Cr..
  • For Profit before tax, as of Dec 2024, the value is ₹691.00 Cr.. The value appears strong and on an upward trend. It has increased from 661.00 Cr. (Sep 2024) to ₹691.00 Cr., marking an increase of ₹30.00 Cr..
  • For Tax %, as of Dec 2024, the value is 27.00%. The value appears to be improving (decreasing) as expected. It has decreased from 31.00% (Sep 2024) to 27.00%, marking a decrease of 4.00%.
  • For Net Profit, as of Dec 2024, the value is ₹503.00 Cr.. The value appears strong and on an upward trend. It has increased from 453.00 Cr. (Sep 2024) to ₹503.00 Cr., marking an increase of ₹50.00 Cr..
  • For EPS in Rs, as of Dec 2024, the value is 14.86. The value appears strong and on an upward trend. It has increased from ₹13.39 (Sep 2024) to 14.86, marking an increase of ₹1.47.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 2:34 pm

MetricMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales 3,2034,1724,6366,6875,8165,9507,6737,9398,0058,5089,62010,72811,302
Expenses 2,5063,2163,6163,9544,4384,6015,6905,7695,5246,0776,7787,3607,662
Operating Profit 6979551,0202,7331,3771,3491,9832,1702,4802,4312,8423,3683,640
OPM % 22%23%22%41%24%23%26%27%31%29%30%31%32%
Other Income 13428632223299-30012157-2884514672
Interest 3459175184206308504451353255333354276
Depreciation 8387191238307409618654658662707808797
Profit before tax 5828449402,3431,0889315621,1871,5261,2261,8472,3522,639
Tax % 25%21%20%26%14%27%22%14%18%37%33%30%
Net Profit 4356647511,7339346784361,0251,2527771,2451,6561,862
EPS in Rs 12.7919.6222.1951.2227.5920.0412.8930.2836.9922.9736.7948.9455.02
Dividend Payout % 45%25%25%34%25%35%66%53%47%105%60%57%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)52.64%13.10%130.76%-46.11%-27.41%-35.69%135.09%22.15%-37.94%60.23%33.01%
Change in YoY Net Profit Growth (%)0.00%-39.54%117.66%-176.86%18.70%-8.28%170.78%-112.95%-60.09%98.17%-27.22%

Torrent Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

No data available for the compounded sales growth chart.

Balance Sheet

Last Updated: November 14, 2024, 6:41 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital 42858585858585858585169169169
Reserves 1,3801,8182,4063,4094,2664,5384,6404,7395,7535,8686,0296,6877,335
Borrowings 6931,1322,7402,3522,5106,4626,0385,7844,8744,0705,3694,0223,128
Other Liabilities 1,6381,9882,5893,0402,7403,1593,3513,4023,3632,8843,0433,6274,456
Total Liabilities 3,7535,0227,8208,8869,60114,24314,11314,01014,07512,90614,61014,50515,088
Fixed Assets 8208752,8332,8593,6887,8557,7487,5337,0656,4238,1218,1387,890
CWIP 2855346781,042519647617712889630765361412
Investments 601862987808044923532181226199173127
Other Assets 2,5873,4274,0114,2064,5895,2495,3955,7635,9405,6285,5245,8346,659
Total Assets 3,7535,0227,8208,8869,60114,24314,11314,01014,07512,90614,61014,50515,088

Below is a detailed analysis of the balance sheet data for Torrent Pharmaceuticals Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2024, the value is ₹169.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹169.00 Cr..
  • For Reserves, as of Sep 2024, the value is ₹7,335.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹6,687.00 Cr. (Mar 2024) to ₹7,335.00 Cr., marking an increase of 648.00 Cr..
  • For Borrowings, as of Sep 2024, the value is ₹3,128.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from ₹4,022.00 Cr. (Mar 2024) to ₹3,128.00 Cr., marking a decrease of 894.00 Cr..
  • For Other Liabilities, as of Sep 2024, the value is ₹4,456.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹3,627.00 Cr. (Mar 2024) to ₹4,456.00 Cr., marking an increase of 829.00 Cr..
  • For Total Liabilities, as of Sep 2024, the value is ₹15,088.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹14,505.00 Cr. (Mar 2024) to ₹15,088.00 Cr., marking an increase of 583.00 Cr..
  • For Fixed Assets, as of Sep 2024, the value is ₹7,890.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹8,138.00 Cr. (Mar 2024) to ₹7,890.00 Cr., marking a decrease of 248.00 Cr..
  • For CWIP, as of Sep 2024, the value is ₹412.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹361.00 Cr. (Mar 2024) to ₹412.00 Cr., marking an increase of 51.00 Cr..
  • For Investments, as of Sep 2024, the value is ₹127.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹173.00 Cr. (Mar 2024) to ₹127.00 Cr., marking a decrease of 46.00 Cr..
  • For Other Assets, as of Sep 2024, the value is ₹6,659.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹5,834.00 Cr. (Mar 2024) to ₹6,659.00 Cr., marking an increase of 825.00 Cr..
  • For Total Assets, as of Sep 2024, the value is ₹15,088.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹14,505.00 Cr. (Mar 2024) to ₹15,088.00 Cr., marking an increase of 583.00 Cr..

Notably, the Reserves (₹7,335.00 Cr.) exceed the Borrowings (3,128.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

No data available for this post.

Free Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow4.00954.00-1.000.00-1.00-5.00-5.00-3.00-2.00-2.00-3.00-1.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days7896125796077687669707463
Inventory Days364297275314318429318362456368298310
Days Payable421421472523356447345345351250224284
Cash Conversion Cycle22-28-71-1302159429317418814789
Working Capital Days334254-12820-17-282897453
ROCE %33%35%27%48%19%13%13%15%17%19%20%23%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Promoters71.25%71.25%71.25%71.25%71.25%71.25%71.25%71.25%71.25%71.25%71.25%68.31%
FIIs10.88%10.80%11.37%12.09%12.04%12.85%13.15%14.08%14.14%14.22%14.46%16.17%
DIIs9.74%10.01%9.40%8.77%8.89%8.22%7.91%7.11%7.15%7.17%6.98%8.25%
Government0.00%0.00%0.10%0.10%0.10%0.10%0.10%0.10%0.10%0.10%0.10%0.10%
Public8.14%7.95%7.87%7.78%7.71%7.59%7.59%7.46%7.34%7.25%7.21%7.17%
No. of Shareholders63,22962,93367,86665,23763,83161,57269,61269,11771,15474,76579,84885,035

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Kotak Emerging Equity Fund - Regular Plan2,309,2531.5584.5390,5002025-03-10491.36%
UTI Flexi Cap Fund1,233,5121.24312.21390,5002025-03-10215.88%
SBI Large & Midcap Fund740,0020.94187.3390,5002025-03-1089.5%
Nippon India Pharma Fund603,3642.22152.72390,5002025-03-1054.51%
Kotak Small Cap Fund - Regular Plan463,7480.81117.38390,5002025-03-1018.76%
Axis Growth Opportunities Fund400,3400.93101.33390,5002025-03-102.52%
Kotak Equity Arbitrage Fund - Regular Plan390,5000.2798.84390,5002025-03-100%
Nippon India Value Fund353,6261.2889.51390,5002025-03-10-9.44%
Franklin India Bluechip Fund - Dividend350,0001.1988.59390,5002025-03-10-10.37%
Franklin India Bluechip Fund - Growth350,0001.1988.59390,5002025-03-10-10.37%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue 5.005.005.005.005.00
Basic EPS (Rs.) 48.9436.7945.9373.9860.55
Diluted EPS (Rs.) 48.9436.7945.9373.9860.55
Cash EPS (Rs.) 72.8257.6785.05112.8499.21
Book Value[Excl.RevalReserv]/Share (Rs.) 202.57183.13351.75344.90284.99
Book Value[Incl.RevalReserv]/Share (Rs.) 202.57183.13351.75344.90284.99
Revenue From Operations / Share (Rs.) 316.96284.23502.72472.97469.12
PBDIT / Share (Rs.) 101.2185.30155.27149.90135.41
PBIT / Share (Rs.) 77.3364.43116.15111.0496.74
PBT / Share (Rs.) 69.4954.5872.4490.1870.11
Net Profit / Share (Rs.) 48.9436.7945.9273.9760.55
NP After MI And SOA / Share (Rs.) 48.9436.7945.9273.9760.55
PBDIT Margin (%) 31.9330.0130.8831.6928.86
PBIT Margin (%) 24.3922.6623.1023.4720.62
PBT Margin (%) 21.9219.2014.4019.0614.94
Net Profit Margin (%) 15.4412.949.1315.6312.90
NP After MI And SOA Margin (%) 15.4412.949.1315.6312.90
Return on Networth / Equity (%) 24.1520.0913.0521.4421.24
Return on Capital Employeed (%) 27.1622.7922.6320.4619.13
Return On Assets (%) 10.998.295.938.897.31
Long Term Debt / Equity (X) 0.230.400.350.500.67
Total Debt / Equity (X) 0.570.850.670.820.90
Asset Turnover Ratio (%) 0.710.680.530.500.47
Current Ratio (X) 1.030.971.201.130.91
Quick Ratio (X) 0.610.560.640.580.51
Inventory Turnover Ratio (X) 0.730.630.680.690.78
Dividend Payout Ratio (NP) (%) 61.2969.3087.0927.0359.45
Dividend Payout Ratio (CP) (%) 41.1944.2147.0217.7236.28
Earning Retention Ratio (%) 38.7130.7012.9172.9740.55
Cash Earning Retention Ratio (%) 58.8155.7952.9882.2863.72
Interest Coverage Ratio (X) 9.698.6610.307.195.08
Interest Coverage Ratio (Post Tax) (X) 5.434.735.954.553.27
Enterprise Value (Cr.) 91136.9056758.9950939.2747229.2337065.09
EV / Net Operating Revenue (X) 8.505.905.995.904.67
EV / EBITDA (X) 26.6019.6619.3818.6216.17
MarketCap / Net Operating Revenue (X) 8.215.415.565.374.20
Retention Ratios (%) 38.7030.6912.9072.9640.54
Price / BV (X) 12.848.397.957.376.92
Price / Net Operating Revenue (X) 8.215.415.565.374.20
EarningsYield 0.010.020.010.020.03

After reviewing the key financial ratios for Torrent Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 24, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 5.00.
  • For Basic EPS (Rs.), as of Mar 24, the value is 48.94. This value is within the healthy range. It has increased from 36.79 (Mar 23) to 48.94, marking an increase of 12.15.
  • For Diluted EPS (Rs.), as of Mar 24, the value is 48.94. This value is within the healthy range. It has increased from 36.79 (Mar 23) to 48.94, marking an increase of 12.15.
  • For Cash EPS (Rs.), as of Mar 24, the value is 72.82. This value is within the healthy range. It has increased from 57.67 (Mar 23) to 72.82, marking an increase of 15.15.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 202.57. It has increased from 183.13 (Mar 23) to 202.57, marking an increase of 19.44.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 202.57. It has increased from 183.13 (Mar 23) to 202.57, marking an increase of 19.44.
  • For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 316.96. It has increased from 284.23 (Mar 23) to 316.96, marking an increase of 32.73.
  • For PBDIT / Share (Rs.), as of Mar 24, the value is 101.21. This value is within the healthy range. It has increased from 85.30 (Mar 23) to 101.21, marking an increase of 15.91.
  • For PBIT / Share (Rs.), as of Mar 24, the value is 77.33. This value is within the healthy range. It has increased from 64.43 (Mar 23) to 77.33, marking an increase of 12.90.
  • For PBT / Share (Rs.), as of Mar 24, the value is 69.49. This value is within the healthy range. It has increased from 54.58 (Mar 23) to 69.49, marking an increase of 14.91.
  • For Net Profit / Share (Rs.), as of Mar 24, the value is 48.94. This value is within the healthy range. It has increased from 36.79 (Mar 23) to 48.94, marking an increase of 12.15.
  • For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 48.94. This value is within the healthy range. It has increased from 36.79 (Mar 23) to 48.94, marking an increase of 12.15.
  • For PBDIT Margin (%), as of Mar 24, the value is 31.93. This value is within the healthy range. It has increased from 30.01 (Mar 23) to 31.93, marking an increase of 1.92.
  • For PBIT Margin (%), as of Mar 24, the value is 24.39. This value exceeds the healthy maximum of 20. It has increased from 22.66 (Mar 23) to 24.39, marking an increase of 1.73.
  • For PBT Margin (%), as of Mar 24, the value is 21.92. This value is within the healthy range. It has increased from 19.20 (Mar 23) to 21.92, marking an increase of 2.72.
  • For Net Profit Margin (%), as of Mar 24, the value is 15.44. This value exceeds the healthy maximum of 10. It has increased from 12.94 (Mar 23) to 15.44, marking an increase of 2.50.
  • For NP After MI And SOA Margin (%), as of Mar 24, the value is 15.44. This value is within the healthy range. It has increased from 12.94 (Mar 23) to 15.44, marking an increase of 2.50.
  • For Return on Networth / Equity (%), as of Mar 24, the value is 24.15. This value is within the healthy range. It has increased from 20.09 (Mar 23) to 24.15, marking an increase of 4.06.
  • For Return on Capital Employeed (%), as of Mar 24, the value is 27.16. This value is within the healthy range. It has increased from 22.79 (Mar 23) to 27.16, marking an increase of 4.37.
  • For Return On Assets (%), as of Mar 24, the value is 10.99. This value is within the healthy range. It has increased from 8.29 (Mar 23) to 10.99, marking an increase of 2.70.
  • For Long Term Debt / Equity (X), as of Mar 24, the value is 0.23. This value is within the healthy range. It has decreased from 0.40 (Mar 23) to 0.23, marking a decrease of 0.17.
  • For Total Debt / Equity (X), as of Mar 24, the value is 0.57. This value is within the healthy range. It has decreased from 0.85 (Mar 23) to 0.57, marking a decrease of 0.28.
  • For Asset Turnover Ratio (%), as of Mar 24, the value is 0.71. It has increased from 0.68 (Mar 23) to 0.71, marking an increase of 0.03.
  • For Current Ratio (X), as of Mar 24, the value is 1.03. This value is below the healthy minimum of 1.5. It has increased from 0.97 (Mar 23) to 1.03, marking an increase of 0.06.
  • For Quick Ratio (X), as of Mar 24, the value is 0.61. This value is below the healthy minimum of 1. It has increased from 0.56 (Mar 23) to 0.61, marking an increase of 0.05.
  • For Inventory Turnover Ratio (X), as of Mar 24, the value is 0.73. This value is below the healthy minimum of 4. It has increased from 0.63 (Mar 23) to 0.73, marking an increase of 0.10.
  • For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 61.29. This value exceeds the healthy maximum of 50. It has decreased from 69.30 (Mar 23) to 61.29, marking a decrease of 8.01.
  • For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 41.19. This value is within the healthy range. It has decreased from 44.21 (Mar 23) to 41.19, marking a decrease of 3.02.
  • For Earning Retention Ratio (%), as of Mar 24, the value is 38.71. This value is below the healthy minimum of 40. It has increased from 30.70 (Mar 23) to 38.71, marking an increase of 8.01.
  • For Cash Earning Retention Ratio (%), as of Mar 24, the value is 58.81. This value is within the healthy range. It has increased from 55.79 (Mar 23) to 58.81, marking an increase of 3.02.
  • For Interest Coverage Ratio (X), as of Mar 24, the value is 9.69. This value is within the healthy range. It has increased from 8.66 (Mar 23) to 9.69, marking an increase of 1.03.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 5.43. This value is within the healthy range. It has increased from 4.73 (Mar 23) to 5.43, marking an increase of 0.70.
  • For Enterprise Value (Cr.), as of Mar 24, the value is 91,136.90. It has increased from 56,758.99 (Mar 23) to 91,136.90, marking an increase of 34,377.91.
  • For EV / Net Operating Revenue (X), as of Mar 24, the value is 8.50. This value exceeds the healthy maximum of 3. It has increased from 5.90 (Mar 23) to 8.50, marking an increase of 2.60.
  • For EV / EBITDA (X), as of Mar 24, the value is 26.60. This value exceeds the healthy maximum of 15. It has increased from 19.66 (Mar 23) to 26.60, marking an increase of 6.94.
  • For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 8.21. This value exceeds the healthy maximum of 3. It has increased from 5.41 (Mar 23) to 8.21, marking an increase of 2.80.
  • For Retention Ratios (%), as of Mar 24, the value is 38.70. This value is within the healthy range. It has increased from 30.69 (Mar 23) to 38.70, marking an increase of 8.01.
  • For Price / BV (X), as of Mar 24, the value is 12.84. This value exceeds the healthy maximum of 3. It has increased from 8.39 (Mar 23) to 12.84, marking an increase of 4.45.
  • For Price / Net Operating Revenue (X), as of Mar 24, the value is 8.21. This value exceeds the healthy maximum of 3. It has increased from 5.41 (Mar 23) to 8.21, marking an increase of 2.80.
  • For EarningsYield, as of Mar 24, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 23) to 0.01, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Torrent Pharmaceuticals Ltd as of March 12, 2025 is: ₹2,424.40

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 12, 2025, Torrent Pharmaceuticals Ltd is Overvalued by 21.13% compared to the current share price 3,074.00

Intrinsic Value of Torrent Pharmaceuticals Ltd as of March 12, 2025 is: 2,624.77

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 12, 2025, Torrent Pharmaceuticals Ltd is Overvalued by 14.61% compared to the current share price 3,074.00

Last 5 Year EPS CAGR: 8.26%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 23.50%, which is a positive sign.
  2. The company has higher reserves (4,528.31 cr) compared to borrowings (3,782.62 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (6.69 cr) and profit (297.69 cr) over the years.
  1. The stock has a high average Working Capital Days of 37.92, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 50.50, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Torrent Pharmaceuticals Ltd:
    1. Net Profit Margin: 15.44%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 27.16% (Industry Average ROCE: 16%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 24.15% (Industry Average ROE: 16.32%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 5.43
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 0.61
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 55.9 (Industry average Stock P/E: 42.42)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.57
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Torrent Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 15/07/1972 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24230GJ1972PLC002126 and registration number is 002126. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 8532.90 Cr. and Equity Capital is Rs. 169.23 Cr. for the Year ended 31/03/2024.
INDUSTRYADDRESSCONTACT
PharmaceuticalsTorrent House, Off Ashram Road, Ahmedabad Gujarat 380009investorservices@torrentpharma.com
http://www.torrentpharma.com
Management
NamePosition Held
Mr. Sudhir MehtaChairman Emeritus
Mr. Samir MehtaExecutive Chairman
Mr. Aman Samir MehtaWhole Time Director
Mr. Jinesh ShahDirector - Operations
Mr. Jinal MehtaNon Executive Director
Mr. Manish Mahendra ChoksiIndependent Director
Dr. Maurice ChagnaudIndependent Director
Mr. Nikhil KhattauIndependent Director
Ms. Ameera ShahIndependent Director
Ms. Nayantara BaliIndependent Director

FAQ

What is the latest intrinsic value of Torrent Pharmaceuticals Ltd?

The latest intrinsic value of Torrent Pharmaceuticals Ltd as on 09 March 2025 is ₹2424.40, which is 21.13% lower than the current market price of 3,074.00, indicating the stock is overvalued by 21.13%. The intrinsic value of Torrent Pharmaceuticals Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹1,04,027 Cr. and recorded a high/low of ₹3,591/2,488 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹7,335 Cr and total liabilities of ₹15,088 Cr.

What is the Market Cap of Torrent Pharmaceuticals Ltd?

The Market Cap of Torrent Pharmaceuticals Ltd is 1,04,027 Cr..

What is the current Stock Price of Torrent Pharmaceuticals Ltd as on 09 March 2025?

The current stock price of Torrent Pharmaceuticals Ltd as on 09 March 2025 is ₹3,074.

What is the High / Low of Torrent Pharmaceuticals Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Torrent Pharmaceuticals Ltd stocks is ₹3,591/2,488.

What is the Stock P/E of Torrent Pharmaceuticals Ltd?

The Stock P/E of Torrent Pharmaceuticals Ltd is 55.9.

What is the Book Value of Torrent Pharmaceuticals Ltd?

The Book Value of Torrent Pharmaceuticals Ltd is 222.

What is the Dividend Yield of Torrent Pharmaceuticals Ltd?

The Dividend Yield of Torrent Pharmaceuticals Ltd is 0.91 %.

What is the ROCE of Torrent Pharmaceuticals Ltd?

The ROCE of Torrent Pharmaceuticals Ltd is 23.2 %.

What is the ROE of Torrent Pharmaceuticals Ltd?

The ROE of Torrent Pharmaceuticals Ltd is 24.2 %.

What is the Face Value of Torrent Pharmaceuticals Ltd?

The Face Value of Torrent Pharmaceuticals Ltd is 5.00.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Torrent Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE